HTTO - Clinical: Serotonin Transporter Genotype, Saliva

Test Catalog

Test Name

Test ID: HTTO    
Serotonin Transporter Genotype, Saliva

Useful For Suggests clinical disorders or settings where the test may be helpful

Qualifying participants for clinical trials

 

Evaluating patients who have failed therapy with selective serotonin reuptake inhibitors (SSRIs)

 

Evaluating patients with treatment-resistant depression

 

Predicting response time to improvement with SSRIs

 

Identifying patients who might respond favorably to nonselective antidepressants

 

Identifying patients who have diminished amounts of the serotonin transporter and, hence, an altered response to SSRI therapeutics

 

Genotyping patients who prefer not to have venipuncture done

Testing Algorithm Delineates situations when tests are added to the initial order. This includes reflex and additional tests.

 

Clinical Information Discusses physiology, pathophysiology, and general clinical aspects, as they relate to a laboratory test

Serotonin (5-hydroxytryptamine; 5-HT) is a neurotransmitter. The serotonin transporter (5-HTT) modulates neurotransmission by facilitating removal of serotonin from the synapse of serotonergic neurons, resulting in serotonin reuptake into the presynaptic terminus. Other designations for 5-HTT are SLC6A4 (solute carrier family 6 [neurotransmitter transporter, serotonin], member 4), hSERT, OCD1, SERT, sodium-dependent serotonin transporter, and 5-HT transporter. 

 

Selective serotonin reuptake inhibitors (SSRIs) block the action of the serotonin transporter and are used to treat depression and other neuropsychiatric disorders. Examples of SSRIs include fluoxetine (Prozac), fluvoxamine (Luvox), escitalopram oxalate (Lexapro), sertraline (Zoloft), citalopram (Celexa), and paroxetine (Paxil, Paxil CR).

 

The 5-HTT gene is located at 17q11.1-q12 and is composed of 14 exons spanning 31 kb. A 44-base pair promoter insertion/deletion polymorphism called LPR, or linked polymorphic region, produces alleles described as long or short. The short allele is dominant and results in decreased concentration of the transporter protein and a poorer response to stressful events. While individuals homozygous for the long allele (l/l) may demonstrate response to SSRI therapy in 3 to 4 weeks, individuals with the short allele (l/s or s/s) may respond to SSRI therapy more slowly, taking up to 12 weeks.

Reference Values Describes reference intervals and additional information for interpretation of test results. May include intervals based on age and sex when appropriate. Intervals are Mayo-derived, unless otherwise designated. If an interpretive report is provided, the reference value field will state this.

An interpretive report will be provided.

Interpretation Provides information to assist in interpretation of the test results

The normal (wildtype) allele yields a long product (l/l). The variant is short/short (s/s). Heterozygotes have a l/s genotype.

 

Individuals homozygous for the long allele (l/l) may respond more rapidly to selective serotonin reuptake inhibitor (SSRI) therapy.

 

Individuals homozygous for the short allele (s/s) may respond more slowly to SSRI therapy and may benefit from a longer trial before considering switching to another antidepressant. Even 1 copy of the short allele (heterozygous) decreases the amount of the transporter protein present, increasing the time to response.

 

For additional information regarding pharmacogenomic genes and their associated drugs, see the Pharmacogenomics Associations Tables in Special Instructions. This resource also includes information regarding enzyme inhibitors and inducers, as well as potential alternate drug choices.

Cautions Discusses conditions that may cause diagnostic confusion, including improper specimen collection and handling, inappropriate test selection, and interfering substances

Samples may contain donor DNA if obtained from patients who received heterologous blood transfusions or allogeneic blood or marrow transplantation. Results from samples obtained under these circumstances may not accurately reflect the recipient's genotype. For individuals who have received blood transfusions, the genotype usually reverts to that of the recipient within 6 weeks. For individuals who have received allogeneic blood or marrow transplantation, a pretransplant DNA specimen is recommended for testing.

 

The test measures only the 5-hydroxytryptamine transporter (5-HTT) (linked polymorphic region) polymorphism and will not indicate the presence of any other polymorphism. A mutation occurring at the site of PCR primer annealing could lead to a heterozygote being incorrectly labeled as a homozygote.

Clinical Reference Recommendations for in-depth reading of a clinical nature

1. Lesch KP, Gutnecht L: Pharmacogenetics of the serotonin transporter. Prog Neuropsychopharmacol Biol Psychiatry 2005;29:1062-1073

2. Genecard at NCBI for 5-HTT. XenneX, Inc. 2005 October 18; Retrieved 1/06; Available at www.genecards.org/cgi-bin/carddisp?SLC6A4&snpcount=49

Special Instructions and Forms Library of PDFs including pertinent information and consent forms, specimen collection and preparation information, test algorithms, and other information pertinent to test